Cerebrospinal fluid and plasma oxidative stress biomarkers in different clinical phenotypes of neuroinflammatory acute attacks. Conceptual accession: From fundamental to clinic

Cellular and Molecular Neurobiology

Volumn 33, Issue 6, 2013, Pages 767-777

  Ljubisavljevic, Srdjan ^a,b   Stojanovic, Ivana ^b   Vojinovic, Slobodan ^a   Stojanov, Dragan ^a   Stojanovic, Svetlana ^b   Kocic, Gordana ^b   Savic, Dejan ^a   Cvetkovic, Tatjana ^b   Pavlovic, Dusica ^b  

^a Clinical Centre Nis   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

Author keywords

Catalase; Clinically isolated syndrome; Malondialdehyde; Relapsing remitting multiple sclerosis; Superoxide dismutase

Indexed keywords

BIOLOGICAL MARKER; CATALASE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; ACUTE DISEASE; BLOOD; CEREBROSPINAL FLUID; DEMOGRAPHY; MIDDLE AGED; PATHOLOGY; PHENOTYPE; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CATALASE; DEMOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MALONDIALDEHYDE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATIVE STRESS; PHENOTYPE; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84881111850     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-013-9944-5     Document Type: Article

References (50)

1. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A (2007) Reactive oxygen species and superoxide dismutases: role in joint disease. Joint Bone Spine 74:324-329
2. Andreeva IL, Kozemjakin AL, Kiskun AA (1988) Modifikacija metoda opredelenia perekisej lipidov v teste s tiobarbiturovoj kislotoj. Lab Delo 11:41-43
3. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA (2004) Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 24:1531-1540
4. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271-278
5. Brex PA, Miszkiel KA, O'Riordan JI, Plant GT, Moseley IF, Thompson AJ, Miller DH (2001) Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 70:390-393
6. Calabrase V, Raffaele R, Cosentino E, Rizza V (1994) Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res 14:119-123
7. Calabrese V, Scapagnini G, Ravagna A, Bella R, Foresti R, Bates TE, Giuffrida Stella AM, Pennisi G (2002) Nitric oxide synthase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and with changes in glutathione levels. J Neurosci Res 70:580-587
8. Dalton CM, Brex PA, Miszkiel KA, Hickman SJ, MacManus DG, Plant GT, Thompson AJ, Miller DH (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52:47-53
9. Erden Inal M, Kanbak G, Sunal E (2001) Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin Chim Acta 305:75-80
10. Ferretti G, Bacchetti T (2011) Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci 311(1):92-97
11. Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11:677-682
12. Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261-268
13. Glabinski A, Tawsek NS, Bartosz G (1993) Increased generation of superoxide radicals in the blood of MS patients. Acta Neurol Scand 88:174-177
14. Goth L (1991) Serum catalase: reversibly formed charge isoform of erythrocyte catalase. Clin Chem 37(2):2043-2047
15. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134(7):1914-1924
16. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451:1076-1081
17. Hunter MI, Nlemadim BC, Davidson DL (1985) Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 10:1645-1652
18. Ilhan A, Akyol O, Gurel A, Armutcu F, Iraz M, Oztas E (2004) Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic Biol Med 37:386-394
19. Jana A, Hogan EL, Pahan K (2009) Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci 278(1):5-15
20. Johnson F, Giulivi C (2005) Superoxide dismutases and their impact upon human health. Mol Aspects Med 26(4-5):340-352
21. Keles MS, Taysi S, Sen N, Aksoy H, Akçay F (2001) Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci 28(2):141-143
22. Koch MW, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, De Keyser J (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 253:483-487
23. Kocha M, Mosterta J, Arutjunyanb AV, Stepanovb M, Teelkena A, Heersemaa D, De Keysera J (2007) Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 14:529-533
24. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
25. Lambeth JD (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4:181-189
26. Liu Y, Hao W, Letiembre M, Walter S, Kulanga M, Neumann H, Fassbender K (2006) Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 26(50):12904-12913
27. Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, Savic D, Pavlovic D (2013) The patients with clinically isolated syndrome and relapsing remitting multiples sclerosis show different levels of advanced protein oxidation products and reduced thiols content in sera and CSF. Neurochem Int 62(7):988-997
28. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey - National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911
29. Miller AF (2004) Superoxide dismutases: active sites that save, but a protein that kills. Curr Opin Chem Biol 8(2):162-168
30. Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M (2011) The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 36:1012-1016
31. Minami M, Yoshikawa H (1979) A simplified assay method of superoxide dismutase activity for clinical use. Clin Chim Acta 92:337-342
32. Mirshafiey A, Mohsenzadegan M (2009) Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 31(1):13-29
33. Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z (2010) Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathol 48(2):116-122
34. Naidoo R, Knapp ML (1992) Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 38:2449-2454
35. Namaki S, Mohsenzadegan M, Mirshafiey A (2009) Superoxide dismutase: a light horizon in treatment of multiple sclerosis. J Chin Clin Med 4(10):585-591
36. Penga F, Yanga Y, Liua J, Jianga Y, Zhua C, Denga X, Hua X, Chena X, Zhongb X (2012) Low antioxidant status of serum uric acid, bilirubin and albumin in patients with neuromyelitis optica. Eur J Neurol 19:277-283
37. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 69(2):292-302
38. Qi X, Guy J, Nick H, Valentine J, Rao N (1997) Increase of manganese superoxide dismutase, but not of Cu/Zn-SOD, in experimental optic neuritis. Invest Ophthalmol Vis Sci 38(6):1203-1212
39. Qi X, Hauswirth WW, Guy J (2007) Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis. Mol Vis 13:1-11
40. Quintana FJ, Yeste A, Weiner HL, Covacu R (2012) Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis. J Neuroimmunol 248(1):53-57
41. Rogovina NI, Koklov AP (1980) Metabolism of lipid peroxidation products in multiple sclerosis patients. Zh Nevropatol Psikhiatr 80:696-700
42. Sbardella E, Greco A, Stromillo ML, Prosperini L, Puopolo M, Cefaro LA, Pantano P, De Stefano N, Minghetti L, Pozzilli C (2012) Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course. Mult Scler. doi: 10.1177/1352458512457721
43. Schreibelt G, van Horssen J, van Rossum S, Dijkstra CD, Drukarch B, de Vries HE (2007) Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 56(2):322-330
44. Segal BH, Leto LT, Gallin JI, Malech HL, Holland SM (2000) Genetic biochemical and clinical features of chronic granulomatous disease. Medicine 79:170-200
45. Singh I, Paintlia AS, Khan M, Stanislaus R, Paintlia MK, Haq E, Singh AK, Contreras MA (2004) Impaired peroxisomal function in the central nervous system with inflammatory disease of experimental autoimmune encephalomyelitis animals and protection by lovastatin treatment. Brain Res 1022(1-2):1-11
46. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AEG, Nagra RM, Tourtellotte WW, Griffiths LR (2003) Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Mol Brain Res 119(2):170-183
47. Tavazzi B, Batocchi AP, Amorini AM, Nociti V, D'Urso S, Longo S, Gullotta S, Picardi M, Lazzarin G (2011) Serum metabolic profile in multiple sclerosis patients. Mult Scler Int. doi: 10.1155/2011/167156
48. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE (2008) Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biol Med 45(12):1729-1737
49. van Horssen J, Witte ME, Schreibelt G, de Vries HE (2011) Radical changes in multiple sclerosis pathogenesis. BBA Mol Basis Dis 1812(2):141-150
50. Yoshida E, Mokunoa K, Aoki S, Takahashi A, Riku S, Murayama T, Yanagi T, Kato K (1994) Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 124:25-31